Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia Patients

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 2, 2024

Primary Completion Date

May 2, 2026

Study Completion Date

November 2, 2026

Conditions
Acute Myeloid Leukemia, Adult
Interventions
DRUG

Vaccines, Peptide

Multi-peptide vaccine cocktail comprising 9 different immunopeptidome-defined mutated and non-mutated AML/ leukemia stem and progenitor cell (LSC)-associated HLA class I and HLA class II peptides. The vaccine cocktail is synthesized and formulated in the GMP-certified Wirkstoffpeptidlabor at the University of Tübingen.

All Listed Sponsors
lead

University Hospital Tuebingen

OTHER